- Investor's Business Daily•8 hours ago
Biogen stock underplayed promising Alzheimer's Disease drug results on investor concern over a patient seizure.
- Reuters•10 hours ago
Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines reflecting the lifesaving cardiovascular effects of Eli Lilly's Jardiance in a move expected to drive up the drug's sales. The forthcoming guidelines from the American Diabetes Association and the American Association of Clinical Endocrinologists follow last Friday's decision by U.S. regulators to expand the health benefits Lilly can claim for Jardiance to include preventing fatal heart attacks and strokes in type 2 diabetes patients.
- American City Business Journals•10 hours ago
Shares of Biogen jumped Thursday afternoon when word leaked that its experimental Alzheimer’s drug, aducanumab, had performed well in an early-stage trial. By the time markets opened Friday morning, investor sentiment was clear: Biogen's aducanumab remains a frontrunner to become the first drug in the world to treat the underlying cause of Alzheimer’s, the sixth leading cause of death in the United States. As of 1 p.m., shares of Biogen (BIIB) were trading at $295.78, an increase of two percent that adds about $2 billion to the company’s market cap.
LLY : Summary for Eli Lilly and Company Common St - Yahoo Finance
Eli Lilly and Company (LLY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||67.53 x 500|
|Ask||67.90 x 300|
|Day's Range||67.22 - 68.17|
|52 Week Range||64.18 - 87.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.51|
|Dividend & Yield||2.04 (3.01%)|
|1y Target Est||N/A|